MDMA self-administration in laboratory animals: A summary of the literature and proposal for future research

Neuropsychobiology

Volumn 60, Issue 3-4, 2009, Pages 130-136

  Schenk, Susan ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

3,4 Methylenedioxymethamphetamine; Drug abuse; Self administration

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; DOPAMINE; ETICLOPRIDE; FENFLURAMINE; HALOPERIDOL; KETANSERIN; SEROTONIN; SEROTONIN TRANSPORTER; VOLINANSERIN;

CONCENTRATION (PARAMETERS); DOPAMINE RELEASE; DRUG ABUSE; DRUG DEPENDENCE; MONKEY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN BINDING; REINFORCEMENT; REVIEW; RODENT; SELF INJECTION; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

ANIMALS; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SELF ADMINISTRATION;

EID: 70449496185     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253549     Document Type: Review

References (81)

1. McGuire P, Fahy T: Chronic paranoid psychosis after misuse of MDMA ('ecstasy'). BMJ 1991; 302: 697.
2. Winstock AR: Chronic paranoid psychosis after misuse of MDMA. BMJ 1991; 302: 1150-1151.
3. Shearman JD, Chapman RW, Satsangi J, Ryley NG, Weatherhead S: Misuse of ecstasy. BMJ 1992; 305: 309.
4. Gorard DA, Davies SE, Clark ML: Misuse of ecstasy. BMJ 1992; 305: 309.
5. Peroutka SJ, Newman H, Harris H: Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1: 273-277.
6. Cohen RS: Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1137-1145.
7. Solowij N, Hall W, Lee N: Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug. Br J Addict 1992; 87: 1161-1172.
8. Beck J, Rosenbaum M: Pursuit of Ecstasy. The MDMA Experience. Albany, State University of New York Press, 1994.
9. Henry JA: Ecstasy and the dance of death. BMJ 1992; 305: 5-6.
10. Hammersley R, Ditton J, Snith I, Short E: Patterns of ecstasy use by drug users. Br J Criminol 1999; 39: 625-647.
11. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105-115.
12. McCambridge J, Mitcheson L, Winstock A, Hunt N: Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction 2005; 100: 1140-1149.
13. Abdallah AB, Scheier LM, Inciardi JA, Copeland J, Cottler LB: A psycho-economic model of ecstasy consumption and related consequences: a multi-site study with community samples. Subst Use Misuse 2007; 42: 1651-1684.
14. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A: Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol 2001; 16: 599-606.
15. Leung KS, Cottler LB: Ecstasy and other club drugs: a review of recent epidemiologic studies. Curr Opin Psychiatry 2008; 21: 234-241.
16. Washton AM, Gold MS: Recent trends in cocaine abuse; a view from the national hotline 800-COCAINE; in Stimmel B (ed): Cocaine: Pharmacology Addiction and Therapy. New York, Haworth Press, 1987, pp 31-48.
17. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J: Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/ MDMA users: a WWW study. Addict Behav 2004; 29: 743-752.
18. Verkes RJ, Gijsman HJ, Pieters MS, Schoemaker RC, De Visser S, Kuijpers M, Pennings EJ, De Bruin D, Van De Wijngaart G, Van Gerven JM, Cohen AF: Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 2001; 153: 196-202.
19. Fox HC, Parrott AC, Turner JJ: Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 2001; 15: 273-281.
20. Parrott AC: Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 2005; 19: 71-83.
21. Verheyden SL, Maidment R, Curran HV: Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol 2003; 17: 371-378.
22. Fischman MW, Schuster CR, Javaid J, Hatano Y, Davis J: Acute tolerance development to the cardiovascular and subjective effects of cocaine. J Pharmacol Exp Ther 1985; 235: 677-682.
23. Ambre JJ, Belknap SM, Nelson J, Ruo TI, Shin SG, Atkinson AJ Jr: Acute tolerance to cocaine in humans. Clin Pharmacol Ther 1988; 44: 1-8.
24. Foltin RW, Fischman MW: Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther 1991; 257: 247-261.
25. Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD: Repeated intranasal cocaine administration: lack of tolerance to pressor effects. Drug Alcohol Depend 1988; 22: 169-177.
26. Beardsley PM, Balster RL, Harris LS: Selfadministration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 1986; 18: 149-157.
27. Lamb RJ, Griffiths RR: Self-injection of d,1- 3,4- methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology 1987; 91: 268-272.
28. Ratzenboeck E, Saria A, Kriechbaum N, Zernig G: Reinforcing effects of MDMA ('ecstasy') in drug-naive and cocaine-trained rats. Pharmacology 2001; 62: 138-144.
29. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G: 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 2002; 161: 356-364.
30. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G: Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 2004; 29: 1270-1281.
31. Fantegrossi WE: In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys. Exp Clin Psychopharmacol 2008; 16: 1-12.
32. Lile JA, Ross JT, Nader MA: A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') with cocaine in rhesus monkeys. Drug Alcohol Depend 2005; 78: 135-140.
33. Wang Z, Woolverton WL: Estimating the relative reinforcing strength of (+/-)- 3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology 2007; 189: 483-488.
34. Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S, Nader MA: Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology 2008; 33: 219-225.
35. Banks ML, Czoty PW, Sprague JE, Nader MA: Influence of thyroid hormones on 3,4-methylenedioxymethamphetamineinduced thermogenesis and reinforcing strength in monkeys. Behav Pharmacol 2008; 19: 167-170.
36. Banks ML, Sprague JE, Czoty PW, Nader MA: Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacology 2008; 196: 63-70.
37. Wakonigg G, Sturm K, Saria A, Zernig G: Methylenedioxymethamphetamine (MDMA, 'ecstasy') serves as a robust positive reinforcer in a rat runway procedure. Pharmacology 2003; 69: 180-182.
38. Braida D, Sala M: Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 2002; 136: 1089-1092.
39. Shin R, Qin M, Liu ZH, Ikemoto S: Intracranial self-administration of MDMA into the ventral striatum of the rat: differential roles of the nucleus accumbens shell, core, and olfactory tubercle. Psychopharmacology 2008; 198: 261-270.
40. Robledo P, Trigo JM, Panayi F, De La Torre R, Maldonado R: Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology 2007; 195: 255-264.
41. Trigo JM, Panayi F, Soria G, Maldonado R, Robledo P: A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology 2006; 184: 212-220.
42. Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch KP, Robledo P, Maldonado R: 3,4- methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol Psychiatry 2007; 62: 669-679.
43. Tourino C, Ledent C, Maldonado R, Valverde O: CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol Psychiatry 2008; 63: 1030-1038.
44. Schenk S, Gittings D, Johnstone M, Daniela E: Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 2003; 169: 21-27.
45. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC: MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 2007; 26: 3229-3236.
46. De La Garza R 2nd, Fabrizio KR, Gupta A: Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology 2007; 189: 425-434.
47. Dalley JW, Laane K, Theobald DE, Pena Y, Bruce CC, Huszar AC, Wojcieszek M, Everitt BJ, Robbins TW: Enduring deficits in sustained visual attention during withdrawal of intravenous methylenedioxymethamphetamine self-administration in rats: results from a comparative study with d-am - phetamine and methamphetamine. Neuropsychopharmacology 2007; 32: 1195-1206.
48. Reveron ME, Maier EY, Duvauchelle CL: Experience- dependent changes in temperature and behavioral activity induced by MDMA. Physiol Behav 2006; 89: 358-363.
49. Ball KT, Walsh KM, Rebec GV: Reinstatement of MDMA (ecstasy) seeking by exposure to discrete drug-conditioned cues. Pharmacol Biochem Behav 2007; 87: 420-425.
50. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, McGregor IS: Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 2003; 482: 339-341.
51. Dickerson SM, Walker DM, Reveron ME, Duvauchelle CL, Gore AC: The recreational drug ecstasy disrupts the hypothalamic-pituitary- gonadal reproductive axis in adult male rats. Neuroendocrinology 2008; 88: 95-102.
52. Schenk S, Hely L, Gittings D, Lake B, Daniela E: Effects of priming injections of MDMA and cocaine on reinstatement of MDMA- and cocaine-seeking in rats. Drug Alcohol Depend 2008; 96: 249-255.
53. Battaglia G, Yeh SY, De Souza EB: MDMAinduced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988; 29: 269-274.
54. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA: Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 1993; 264: 1484-1491.
55. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW: (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988; 260: 51-55.
56. Ricaurte GA, Martello AL, Katz JL, Martello MB: Lasting effects of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 1992; 261: 616-622.
57. Fantegrossi WE: Reinforcing effects of methylenedioxyamphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology 2007; 189: 471-482.
58. Steele TD, McCann UD, Ricaurte GA: 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): pharmacology and toxicology in animals and humans. Addiction 1994; 89: 539-551.
59. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M: A voxel-based PET investigation of the long-term effects of 'Ecstasy' consumption on brain serotonin transporters. Am J Psychiatry 2004; 161: 1181-1189.
60. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA: Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C] DASB. Neuropsychopharmacology 2005; 30: 1741-1750.
61. Gouzoulis-Mayfrank E, Daumann J: Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101: 348-361.
62. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL: Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 2005; 313: 848-854.
63. Cole JC, Sumnall HR: The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003; 27: 199-217.
64. Shankaran M, Gudelsky GA: A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology 1999; 147: 66-72.
65. Amato JL, Bankson MG, Yamamoto BK: Prior exposure to chronic stress and MDMA potentiates mesoaccumbens dopamine release mediated by the 5-HT 1B receptor. Neuropsychopharmacology 2007; 32: 946-954.
66. Daniela E, Brennan K, Gittings D, Hely L, Schenk S: Effect of SCH 23390 on (+/-)-3,4- methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav 2004; 77: 745-750.
67. Daniela E, Gittings D, Schenk S: Conditioning following repeated exposure to MDMA in rats: role in the maintenance of MDMA self-administration. Behav Neurosci 2006; 120: 1144-1150.
68. Schechter MD: Serotonergic-dopaminergic mediation of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Biochem Behav 1988; 31: 817-824.
69. Bondareva T, Weso?owska A, Dukat M, Lee M, Young R, Glennon RA: S (+)- and R (-)Nmethyl- 1-(3,4-methylenedioxyphenyl)-2- aminopropane (MDMA) as discriminative stimuli: effect of cocaine. Pharmacol Biochem Behav 2005; 82: 531-538.
70. Kueh D, Baker LE: Reinforcement schedule effects in rats trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or cocaine. Psychopharmacology 2007; 189: 447-457.
71. Khorana N, Pullagurla MR, Dukat M, Young R, Glennon RA: Stimulus effects of three sulfur- containing psychoactive agents. Pharmacol Biochem Behav 2004; 78: 821-826.
72. Bubar MJ, Pack KM, Frankel PS, Cunningham KA: Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)- MDMA. Psychopharmacology 2004; 173: 326-336.
73. Goodwin AK, Pynnonen DM, Baker LE: Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination. Pharmacol Biochem Behav 2003; 74: 987-995.
74. Goodwin AK, Baker LE: A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (+/-)-MDMA in rats. Exp Clin Psychopharmacol 2000; 8: 415-423.
75. Schechter MD: Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination. Pharmacol Biochem Behav 1991; 38: 539-544.
76. Johanson CE, Kilbey M, Gatchalian K, Tancer M: Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 2006; 81: 27-36.
77. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531.
78. Lott DC, Kim SJ, Cook EH, De Wit H: Serotonin transporter genotype and acute subjective response to amphetamine. Am J Addict 2006; 15: 327-335.
79. Reneman L, Schilt T, De Win MM, Booij J, Schmand B, Van Den Brink W, Bakker O: Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharmacol 2006; 20: 389-399.
80. Szilagyi A, Boor K, Szekely A, Gaszner P, Kalasz H, Sasvari-Szekely M, Barta C: Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence. Neuropsychopharmacol Hung 2005; 7: 28-33.
81. Ahmed SH, Lutjens R, Van Der Stap LD, Lekic D, Romano-Spica V, Morales M, Koob GF, Repunte-Canonigo V, Sanna PP: Gene expression evidence for remodeling of lateral hypothalamic circuitry in cocaine addiction. Proc Natl Acad Sci USA 2005; 102: 11533-11538.